News Spark and Pfizer's haemophilia gene therapy gets European PR... Decision based on promising data from ongoing phase 1/2 trial.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.